drugset / Trial / NCT03828084

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

NCT03828084

Phase 1 Completed 16 enrolled EpiDestiny, Inc.
RandomizedCrossoverOpen-labelOther

Summary

To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.

Timeline

Start
2019-04-03
Primary completion
2019-05-02
Completion
2019-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 15 mg Oral
Subject Tetrahydrouridine Small molecule 750 mg Oral

Indications

No indication recorded.